Rad51 Promoter-Targeted Gene Therapy Is Effective for In Vivo Visualization and Treatment of Cancer
Open Access
- 1 February 2012
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 20 (2) , 347-355
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Comparisons of three polyethyleneimine-derived nanoparticles as a gene therapy delivery system for renal cell carcinomaJournal of Translational Medicine, 2011
- Patterns of Expression of DNA Repair Genes and Relapse From MelanomaClinical Cancer Research, 2010
- Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and RepairMolecular Cell, 2010
- Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapyCancer Chemotherapy and Pharmacology, 2009
- Overexpression of RAD51 occurs in aggressive prostatic cancerHistopathology, 2009
- Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instabilityNucleic Acids Research, 2009
- Nanoparticle-Delivered Suicide Gene Therapy Effectively Reduces Ovarian Tumor Burden in MiceCancer Research, 2009
- Use of the Rad51 promoter for targeted anti-cancer therapyProceedings of the National Academy of Sciences, 2008
- Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapyThe Prostate, 2008
- Mesothelin targeted cancer immunotherapyEuropean Journal of Cancer, 2008